相关实验视频

Updated: Jan 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

阿利罗马布对冠状动脉斑块的影响,由动脉血风险分层分层

Yasushi Ueki¹, Ryota Kakizaki², Tatsuhiko Otsuka²

¹Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Cardiovascular Medicine, Shinshu University Hospital, Matsumoto, Japan.

Atherosclerosis

|November 28, 2025

概括

添加于他类药物治疗的阿利罗库马布在急性心肌梗塞患者中显示出较大的冠状动脉斑块回归,而这些患者的风险不是很高. 这表明动脉血栓风险影响斑块稳定和回归与PCSK9抑制.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
医疗成像医学成像

背景情况:

抑制蛋白转化酶亚素/素9型 (PCSK9) 提供心血管方面的好处,特别是在高风险患者中.
在高动脉血风险患者中,PCSK9抑制剂更大益处的机制尚不清楚.
这项研究研究了阿利罗库马布对急性心肌梗塞 (AMI) 患者冠状动脉斑块回归的影响,根据风险分层.

研究的目的:

评估阿利罗库马布对AMI患者冠状动脉斑块特征的影响.
根据AHA/ACC指南定义的风险类别对斑块回归进行分层.
在高风险人群中探索增强心血管益处的机制.

主要方法:

随机,双盲PACMAN-AMI试验的子研究.
每两周一次的阿利罗库马布 (150毫克) 加上高强度的他与安慰剂在AMI患者的皮肤穿透冠状动脉干预后.
序列血管内超声波 (IVUS),近红外光谱学 (NIRS) 和光学连贯性断层扫描 (OCT) 在基线和52周进行.
根据先前的事件或高风险状况,被归类为非常高风险 (VHR) 的患者.

主要成果:

与VHR患者相比,非VHR患者观察到的动脉瘤体积 (PAV) 百分比减少较大,而非VHR患者与alirocumab.
在非VHR患者中显著降低脂质负担 (maxLCBI4mm) 和巨角.
纤维帽厚度 (FCT) 的增加在VHR组中更加明显.
治疗和风险类别之间的相互作用对于maxLCBI4mm和巨细胞角度是显著的.

结论:

在非VHR AMI患者中,阿利罗库马布加高强度他类药物治疗促进了更大的冠状动脉斑块回归和脂质减少.
这些发现突出了基于动脉瘤风险的差异性斑块反应.
需要进一步的研究来阐明动脉血栓风险在斑块回归和风险降低策略中的作用.

关键词:

动脉样硬化是一种动脉样硬化.血管内超声波血管内超声波心肌梗塞的心脏病发作近红外光谱学近红外光谱学光学连贯性断层扫描仪

更多相关视频

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...